ArticleLeukemia2023

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.

Riccardo Bomben et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.